Clear Search

Showing 94 results for “Lupus Erythematosus”.

January 2022

Treatment of refractory subacute cutaneous lupus erythematosus with baricitinib

Clin Exp Dermatol. 2021. Epub ahead of print

Phase II data and two individual case reports have shown significant improvement in signs and symptoms of disease in patients with systemic lupus erythematosus (SLE) receiving baricitinib. This case study by Joos et al. reports a further patient with SLE treated successfully with baricitinib.

more…

2019-EULAR/ACR Classification Criteria Domains at Diagnosis: Predictive Factors of Long-Term Damage In Systemic Lupus Erythematosus

Clin Rheumatol. 2021. Epub ahead of print

Single-centre, retrospective analysis identifying that specific domains in the 2019-EULAR/ACR criteria at diagnosis are associated with long-term organ-specific damage, particularly renal and neuropsychiatric harm.

more…

November 2021

Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus: A Randomized Controlled Trial

Ann Intern Med. 2021. Epub ahead of print. doi: 10.7326/M21-2078.

Preliminary evidence suggests that belimumab after rituximab could be developed as a therapeutic strategy for patients with Systemic Lupus Erythematosus (SLE) refractory to conventional therapy.

more…

October 2021

Two-Year, Randomised, Controlled Trial of Belimumab in Lupus Nephritis

N Engl J Med. 2020;383(12):1117–28.

LN occurs in 25–60% of patients with SLE. However, patients with LN are often excluded from clinical trials of SLE therapies.

more…